Hideyoshi Noji
Overview
Explore the profile of Hideyoshi Noji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishiyama K, Yonemura Y, Kawaguchi T, Hosokawa K, Sugimori C, Ueda Y, et al.
Br J Haematol
. 2023 Sep;
203(3):468-476.
PMID: 37654088
To determine the prevalence and clinical relevance of glycosylphosphatidylinositol-anchored protein-deficient (GPI[-]) cell populations (paroxysmal nocturnal haemoglobinuria [PNH]-type cells) in patients with acquired aplastic anaemia (AA) or myelodysplastic syndrome (MDS), we...
2.
Nishimura J, Ando K, Masuko M, Noji H, Ito Y, Mayer J, et al.
Haematologica
. 2022 Mar;
107(6):1483-1488.
PMID: 35263983
No abstract available.
3.
Ikezoe T, Noji H, Ueda Y, Kanda Y, Okamoto S, Usuki K, et al.
Int J Hematol
. 2022 Feb;
115(4):470-480.
PMID: 35146630
All Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab were enrolled in post-marketing surveillance (PMS) between June 2010 and August 2019 to assess the long-term effectiveness and safety...
4.
Hosokawa K, Ishiyama K, Ikemoto T, Sugimori C, Noji H, Shichishima T, et al.
Ann Hematol
. 2020 Oct;
100(8):1975-1982.
PMID: 33095337
Small populations of glycosylphosphatidylinositol-anchored protein-deficient (GPI[-]) cells accounting for up to 0.01% of total granulocytes can be accurately detected by a high-sensitivity flow cytometry (FCM) assay established by the Clinical...
5.
Mori J, Kaji S, Kawai H, Kida S, Tsubokura M, Fukatsu M, et al.
Sci Rep
. 2020 Sep;
10(1):14734.
PMID: 32895431
In this study, we developed the world's first artificial intelligence (AI) system that assesses the dysplasia of blood cells on bone marrow smears and presents the result of AI prediction...
6.
Ishiyama K, Nakao S, Usuki K, Yonemura Y, Ikezoe T, Uchiyama M, et al.
Int J Hematol
. 2020 Sep;
112(4):466-476.
PMID: 32869125
Ravulizumab demonstrated noninferior efficacy and comparable safety to eculizumab in two open-label, phase 3 studies in patients with paroxysmal nocturnal hemoglobinuria (PNH) who complement inhibitor-naive (Study 301) or were previously...
7.
Onishi Y, Yokoyama H, Katsuoka Y, Ito T, Kimura T, Yamamoto J, et al.
Ann Hematol
. 2020 Sep;
99(10):2351-2356.
PMID: 32865607
Lenalidomide (Len) and dexamethasone (dex) therapy is a standard therapy in patients with multiple myeloma. Elderly or unfit patients may reduce Len or dex doses to prevent toxicities that lead...
8.
Abe Y, Noji H, Miura T, Sugai M, Kurosu Y, Ujiie R, et al.
J Radiat Res
. 2019 Oct;
60(6):729-739.
PMID: 31665444
In our previous study, we found that chromosomes were damaged by the radiation exposure from a single computed tomography (CT) examination, based on an increased number of dicentric chromosomes (Dics)...
9.
Mita M, Shichishima T, Noji H, Takahashi H, Nakamura K, Ikezoe T
Hemasphere
. 2019 Mar;
2(5):e142.
PMID: 30887006
No abstract available.
10.
Kameoka Y, Akagi T, Murai K, Noji H, Kato Y, Sasaki O, et al.
Int J Hematol
. 2018 Jul;
108(5):510-515.
PMID: 30043334
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is widely used as a salvage therapy for relapsed or high-risk diffuse large B-cell lymphoma (DLBCL). To investigate the safety and...